Diabetic and Nondiabetic Patients With Left Main and/or 3-Vessel Coronary Artery DiseaseComparison of Outcomes With Cardiac Surgery and Paclitaxel-Eluting Stents
Adrian P. Banning, MD*,*,
Stephen Westaby, MS, PhD*,
Marie-Claude Morice, MD ,
A. Pieter Kappetein, MD, PhD ,
Friedrich W. Mohr, MD ,
Sergio Berti, MD||,
Mattia Glauber, MD||,
Mirle A. Kellett, MD¶,
Robert S. Kramer, MD¶,
Katrin Leadley, MD#,
Keith D. Dawkins, MD# and
Patrick W. Serruys, MD, PhD
* John Radcliffe Hospital, Oxford, United Kingdom
Institut Hospitalier Jacques Cartier, Massy, France
Thorax Center, Erasmus University Medical Center, Rotterdam, the Netherlands
Herzzentrum Universität Leipzig, Leipzig, Germany
|| Institute of Clinical Physiology, CNR Massa, Massa, Italy
¶ Maine Medical Center, Portland, Maine
# Boston Scientific Corporation, Natick, Massachusetts
View larger version (34K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 1 Diabetic Patient Outcomes According to SYNTAX Score Tercile
One-year rates of (A) composite death/cerebrovascular accident (CVA)/myocardial infarction (MI), (B) MI, (C) revascularization, (D) major adverse cardiac and cerebrovascular events (MACCE), (E) CVA, and (F) all-cause death in diabetic patients treated with coronary artery bypass graft surgery (CABG) or TAXUS paclitaxel-eluting stents (PES). Rates are separated by the SYNTAX study scores indicating low (0 to 22), medium (23 to 32), and high ( 33) anatomic lesion complexity.
|
|
|
for this article